The final guidance from the U.S. FDA on Computer Software Assurance (CSA) for Production and Quality Management System software, updated in February 2026, represents a meaningful evolution from the agency’s 2003 Computer System Validation (CSV) guidance. While CSV emphasized documented evidence of testing, CSA sharpens the focus on applying critical thinking and a risk-based approach to validation. The intent is clear: apply the least burdensome method necessary to provide assurance that software is fit for its intended use, without compromising patient safety, product quality, or data integrity.
From CSV to CSA
One of the most persistent misconceptions about CSA is that it reduces or eliminates documentation. It does not. CSA reframes validation activities to ensure documentation is purposeful rather than performative. Instead of generating large volumes of templated deliverables to satisfy a perceived checklist, organizations are encouraged to document what truly demonstrates that the system performs as intended and that risks have been appropriately identified and mitigated.
Under CSA, the level of documentation and testing rigor should align directly with system risk and impact. Software features that directly affect product quality, patient safety, or regulatory reporting warrant more robust testing and evidence. Conversely, low-risk functionality should not be subjected to the same exhaustive validation package simply for the sake of consistency. This shift allows validation teams to allocate effort where it matters most, improving both efficiency and compliance posture.
Why leverage supplier documentation?
A core principle within CSA is the evaluation and leveraging of supplier documentation. Rather than duplicating testing that a qualified vendor has already performed, organizations are encouraged to assess supplier quality systems, review existing validation artifacts, and determine what evidence can be reasonably relied upon. This may include supplier testing documentation, development lifecycle controls, and defect management processes. When suppliers demonstrate mature quality practices, their documentation can meaningfully reduce redundant testing while maintaining regulatory confidence.
This approach does not mean blind reliance on vendors. It requires structured supplier assessment, defined acceptance criteria, and documented justification for leveraging external evidence. The objective is intelligent reliance, not avoidance of responsibility.
A CSA-aligned validation strategy ultimately prioritizes risk-based assurance over rigid methodology. By tailoring validation activities to system impact and thoughtfully leveraging supplier documentation, organizations can reduce low-value deliverables and focus their efforts on high-risk functionality that truly affects compliance and patient safety.
Watch the corresponding video segment to learn more about how CSA best practices evolved and see how CSA changes the role of supplier documentation, and how organizations can apply this approach in practice.
This publication contains general information only and Sikich is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or any other professional advice or services. This publication is not a substitute for such professional advice or services, nor should you use it as a basis for any decision, action or omission that may affect you or your business. Before making any decision, taking any action or omitting an action that may affect you or your business, you should consult a qualified professional advisor. In addition, this publication may contain certain content generated by an artificial intelligence (AI) language model. You acknowledge that Sikich shall not be responsible for any loss sustained by you or any person who relies on this publication.
